SYNJ2BP-COX16

Across TCGA pan-cancer cohorts, SYNJ2BP-COX16 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated SYNJ2BP-COX16 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher SYNJ2BP-COX16 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SYNJ2BP-COX16 expression acts as an unfavorable survival marker.

LIHC are the cancer types where SYNJ2BP-COX16 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.040	0.553	<.001	18	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

SYNJ2BP-COX16–LIHC (DFS)

Open the LIHC breakdown →